Confirmation of EP300 gene mutations as a rare cause of Rubinstein-Taybi syndrome
- PMID: 17299436
- DOI: 10.1038/sj.ejhg.5201791
Confirmation of EP300 gene mutations as a rare cause of Rubinstein-Taybi syndrome
Abstract
The Rubinstein-Taybi syndrome (RSTS, MIM 180849), a dominant Mendelian disorder with typical face, short stature, skeletal abnormalities, and mental retardation, is usually caused by heterozygous mutations of the CREBBP gene, but recently, EP300 gene mutations were reported in three individuals. Using quantitative PCR (for the CREBBP and EP300 genes) and genomic sequencing (for the EP300 gene), we studied here 13 patients who had shown no mutation after genomic sequencing of the CREBBP gene in a previous investigation. Two new disease-causing mutations were identified, including a partial deletion of CREBBP and a 1-bp deletion in EP300, c.7100delC (p.P2366fsX2401). The 1-bp deletion represents the fourth EP300 mutation reported to date and was identified in a patient with non-classical RSTS. Based on the very similar structure of the CREBBP and EP300 genes and the higher rate of single-nucleotide polymorphisms in EP300 (2.23 per individual) as compared to CREBBP (0.71 per individual) (P>0.001, Wilcoxon test), it may be assumed that EP300 gene mutations should be as frequent as CREBBP gene mutations. Based on the location of the EP300 gene mutations identified so far (outside the histone acetyl transferase domain) and the observed (although not very striking) phenotypical differences with the EP300 mutations, we propose that most EP300 mutations could be associated with other phenotypes, not classical RSTS.
Similar articles
-
Rubinstein-Taybi syndrome: clinical and molecular overview.Expert Rev Mol Med. 2007 Aug 20;9(23):1-16. doi: 10.1017/S1462399407000415. Expert Rev Mol Med. 2007. PMID: 17942008 Review.
-
Genetic heterogeneity in Rubinstein-Taybi syndrome: delineation of the phenotype of the first patients carrying mutations in EP300.J Med Genet. 2007 May;44(5):327-33. doi: 10.1136/jmg.2006.046698. Epub 2007 Jan 12. J Med Genet. 2007. PMID: 17220215 Free PMC article.
-
From Whole Gene Deletion to Point Mutations of EP300-Positive Rubinstein-Taybi Patients: New Insights into the Mutational Spectrum and Peculiar Clinical Hallmarks.Hum Mutat. 2016 Feb;37(2):175-83. doi: 10.1002/humu.22922. Epub 2015 Nov 4. Hum Mutat. 2016. PMID: 26486927
-
Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the clinical and genetic spectrum.BMC Med Genet. 2018 Mar 5;19(1):36. doi: 10.1186/s12881-018-0548-2. BMC Med Genet. 2018. PMID: 29506490 Free PMC article.
-
Rubinstein-Taybi Syndrome and Epigenetic Alterations.Adv Exp Med Biol. 2017;978:39-62. doi: 10.1007/978-3-319-53889-1_3. Adv Exp Med Biol. 2017. PMID: 28523540 Free PMC article. Review.
Cited by
-
Exome Sequencing Identification of EP300 Mutation in a Proband with Coloboma and Imperforate Anus: Possible Expansion of the Phenotypic Spectrum of Rubinstein-Taybi Syndrome.Mol Syndromol. 2015 Jul;6(2):99-103. doi: 10.1159/000375542. Epub 2015 Mar 3. Mol Syndromol. 2015. PMID: 26279656 Free PMC article.
-
Protein lysine acetylation by p300/CBP.Chem Rev. 2015 Mar 25;115(6):2419-52. doi: 10.1021/cr500452k. Epub 2015 Jan 16. Chem Rev. 2015. PMID: 25594381 Free PMC article. Review. No abstract available.
-
Role of Non-Coding Regulatory Elements in the Control of GR-Dependent Gene Expression.Int J Mol Sci. 2021 Apr 20;22(8):4258. doi: 10.3390/ijms22084258. Int J Mol Sci. 2021. PMID: 33923915 Free PMC article.
-
Osteoarthritis as an Enhanceropathy: Gene Regulation in Complex Musculoskeletal Disease.Curr Rheumatol Rep. 2024 Jun;26(6):222-234. doi: 10.1007/s11926-024-01142-z. Epub 2024 Mar 2. Curr Rheumatol Rep. 2024. PMID: 38430365 Free PMC article. Review.
-
Rubinstein-Taybi Syndrome: A Model of Epigenetic Disorder.Genes (Basel). 2021 Jun 24;12(7):968. doi: 10.3390/genes12070968. Genes (Basel). 2021. PMID: 34202860 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous